These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 15180471)

  • 1. Targeting tumor necrosis factor-alpha in the therapy of psoriasis.
    Gisondi P; Gubinelli E; Cocuroccia B; Girolomoni G
    Curr Drug Targets Inflamm Allergy; 2004 Jun; 3(2):175-83. PubMed ID: 15180471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases.
    LaDuca JR; Gaspari AA
    Dermatol Clin; 2001 Oct; 19(4):617-35. PubMed ID: 11705350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.
    Markham T; Mullan R; Golden-Mason L; Rogers S; Bresnihan B; Fitzgerald O; Fearon U; Veale DJ
    J Am Acad Dermatol; 2006 Jun; 54(6):1003-12. PubMed ID: 16713454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
    Mössner R; Reich K
    Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis.
    Fantuzzi F; Del Giglio M; Gisondi P; Girolomoni G
    Expert Opin Ther Targets; 2008 Sep; 12(9):1085-96. PubMed ID: 18694376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
    Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis.
    Krueger G; Callis K
    Arch Dermatol; 2004 Feb; 140(2):218-25. PubMed ID: 14967799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-alpha inhibitors for ankylosing spondylitis.
    Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD005468. PubMed ID: 25887212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy in patients with psoriasis and psoriatic arthritis in Indian population.
    Sarkar S; Panda S; Kim B; Raychaudhuri SK; Ghosh A; Raychaudhuri SP
    Indian J Dermatol Venereol Leprol; 2020; 86(1):1-7. PubMed ID: 31719235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review.
    Brezinski EA; Follansbee MR; Armstrong EJ; Armstrong AW
    Curr Pharm Des; 2014; 20(4):513-28. PubMed ID: 23565632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of TNF-α inhibitors in psoriasis.
    Vergou T; Moustou AE; Sfikakis PP; Antoniou C; Stratigos AJ
    Expert Rev Clin Pharmacol; 2011 Jul; 4(4):515-23. PubMed ID: 22114860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential use of infliximab and etanercept in generalized pustular psoriasis.
    Weisenseel P; Prinz JC
    Cutis; 2006 Sep; 78(3):197-9. PubMed ID: 17036664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study.
    Di Lernia V; Ricci C; Lallas A; Ficarelli E
    J Dermatolog Treat; 2014 Feb; 25(1):73-4. PubMed ID: 23621374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Infliximab].
    Herrera E; Habicheyn S
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis.
    Tan X; Balkrishnan R; Feldman SR
    J Drugs Dermatol; 2013 Mar; 12(3):e41-5. PubMed ID: 23545925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The psoriatic patient profile for infliximab.
    Gisondi P; Malara G; Ardigò M
    Eur Rev Med Pharmacol Sci; 2011 Dec; 15(12):1445-51. PubMed ID: 22288305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor (TNF) inhibitors revolutionalized therapy for both psoriasis and psoriatic arthritis. Foreword.
    Gottlieb AB
    Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S3-4. PubMed ID: 24777570
    [No Abstract]   [Full Text] [Related]  

  • 20. New development in the treatment of psoriasis--infliximab.
    Pietrzak A; Chodorowska G; Jazienicka I; Junak-Bojarska A; Roliński J
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):322-7. PubMed ID: 15315008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.